Straddling a Murky Line Between Drugs and Less-Regulated Supplements Illustrates Next Chapter of AstraZeneca’s Aggressive Chinese Penetration Strategy

Straddling a Murky Line Between Drugs and Less-Regulated Supplements Illustrates Next Chapter of AstraZeneca’s Aggressive Chinese Penetration Strategy

AstraZeneca Plc is has announced an incredibly risky—and expensive—early stage oncology strategy to differentiate in major markets such as the U.S. and Europe. However, in China the British Pharma is betting on a traditional heart remedy that be purchased for $2.50 a...

Pin It on Pinterest